Showing 641 - 660 results of 19,677 for search '(( significantly increased decrease ) OR ( significant ((new decrease) OR (a decrease)) ))', query time: 0.67s Refine Results
  1. 641
  2. 642
  3. 643

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  4. 644

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  5. 645

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  6. 646
  7. 647
  8. 648
  9. 649
  10. 650
  11. 651
  12. 652

    Fig 10 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  13. 653

    Fig 4 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  14. 654

    Fig 9 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  15. 655

    Fig 6 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  16. 656

    Fig 7 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  17. 657

    Fig 8 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  18. 658
  19. 659
  20. 660